The treatment of multiple sclerosis (MS) has changed over the last 20 years. All
immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a …

The treatment of multiple sclerosis (MS), the most common chronic inflammatory,
demyelinating and neurodegenerative disease of the central nervous system (CNS) …

Background Treatment options for patients with secondary progressive multiple sclerosis are
few. Encouraging results in open-label studies prompted this randomised trial of …

Although recent animal studies have fuelled growing interest in Ab-independent functions of
B cells, relatively little is known about how human B cells and their subsets may contribute to …

Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …

Objective: To assess in multiple sclerosis (MS) the effect of intense immunosuppression
followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone …

In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune
diseases (ADs) were published, while an international coordinated clinical programme was …

Multiple sclerosis (MS) is commonly regarded as an inflammatory disease, but it also has a
neurodegenerative component, which represents an additional target for treatment. The use …

Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central
nervous system (CNS), affecting more than 2 million people worldwide. It is characterized by …

Background Different therapeutic strategies are available for treatment of multiple sclerosis
(MS) including immunosuppressants, immunomodulators, and monoclonal antibodies. Their …